Literature DB >> 19361026

Increased accuracy in heparin and protamine administration decreases bleeding: a pilot study.

Marx Runge1, Christian H Møller, Daniel A Steinbrüchel.   

Abstract

Three to 5 percent of the patients undergoing cardiac surgery are reoperated because of bleeding. When a surgical cause can be excluded, heparin/protamine mismatch may be considered. Insufficient reversal of heparin and overdosing of protamine may cause postoperative bleeding. The purpose of the study was to evaluate whether a heparin-protamine titration system, Hemochron RxDx, could reduce postoperative bleeding and blood transfusion. Fifty-three patients were included prospectively over a 6-month period. The test group (RxDx group; 28 patients) received heparin and protamine doses calculated using the Hemochron RxDx system, which performs a baseline activated clotting time (ACT) value together with a heparin response test. An accurate heparin dose was calculated based on the Bull dose/response curve. Protamine doses were calculated by the same method. In the control group (25 patients), heparin was administered based on weight (3.5 mg/kg) and monitored by ACT. Heparin was reversed with protamine (1 mg/l mg of total heparin). Postoperative bleeding was significantly lower in the RxDx group (375 mL; range, 125-700 mL) compared with the control group (600 mL; range, 250-1920 mL; p = .018). A reduced number of patients needed blood transfusions in the RxDx group, although this was not statistically significant (19% vs. 38%, respectively; p = .13). Initial heparin dose was significantly reduced in the RxDx group (250 mg; range, 100-375 mg) compared with the control group (300 mg; range, 200-350 mg; p = .04). The additional heparin during cardiopulmonary bypass (CPB) was significantly lower as well 62 (range, 0-185) vs. 100 mg (range, 0-350 mg); p = .04. Initial protamine dose was reduced in the RxDx group 200 (range, 75-340) vs. 350 mg (range, 200-500 mg); p = .0001. Satisfactory end ACT values were obtained in both groups. Using the Hemochron RxDx, we observed a significant reduction in postoperative blood loss, as well as the amount of heparin and initial doses of protamine used during CPB. Individual patient managed anticoagulation during cardiac surgery using dose/response curve techniques based on in vitro analysis of heparin and protamine seems to reduce bleeding.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19361026      PMCID: PMC4680217     

Source DB:  PubMed          Journal:  J Extra Corpor Technol        ISSN: 0022-1058


  18 in total

1.  Hemostatic effects of low-dose protamine following cardiopulmonary bypass.

Authors:  T Miyashita; T Nakajima; Y Hayashi; M Kuro
Journal:  Am J Hematol       Date:  2000-06       Impact factor: 10.047

2.  A retrospective study on perfusion incidents and safety devices.

Authors:  B L Mejak; A Stammers; E Rauch; S Vang; T Viessman
Journal:  Perfusion       Date:  2000-01       Impact factor: 1.972

3.  A new practical technique to reduce allogeneic blood exposure and hospital costs while preserving clotting factors after cardiopulmonary bypass: the Hemobag.

Authors:  Keith A Samolyk; Scott R Beckmann; Randall C Bissinger
Journal:  Perfusion       Date:  2005-10       Impact factor: 1.972

4.  A provincial program of blood conservation: The Ontario Transfusion Coordinators (ONTraC).

Authors:  J Freedman; K Luke; N Monga; S Lincoln; R Koen; M Escobar; J Chiavetta
Journal:  Transfus Apher Sci       Date:  2005-10-04       Impact factor: 1.764

5.  Australasian perfusion incident survey.

Authors:  O F Jenkins; R Morris; J M Simpson
Journal:  Perfusion       Date:  1997-09       Impact factor: 1.972

6.  Predictors of homologous blood transfusion for patients undergoing open heart surgery.

Authors:  J Litmathe; U Boeken; P Feindt; E Gams
Journal:  Thorac Cardiovasc Surg       Date:  2003-02       Impact factor: 1.827

7.  Heparin therapy during extracorporeal circulation. II. The use of a dose-response curve to individualize heparin and protamine dosage.

Authors:  B S Bull; W M Huse; F S Brauer; R A Korpman
Journal:  J Thorac Cardiovasc Surg       Date:  1975-05       Impact factor: 5.209

Review 8.  Coagulation disorders of cardiopulmonary bypass: a review.

Authors:  Domenico Paparella; Stephanie J Brister; Michael R Buchanan
Journal:  Intensive Care Med       Date:  2004-07-24       Impact factor: 17.440

9.  Survey: retrospective survey of monitoring/safety devices and incidents of cardiopulmonary bypass for cardiac surgery in France.

Authors:  Jean-Mathias Charrière; Jérôme Pélissié; Christophe Verd; Philippe Léger; Philippe Pouard; Charles de Riberolles; Pascal Menestret; Marie-Claude Hittinger; Dan Longrois
Journal:  J Extra Corpor Technol       Date:  2007-09

10.  Increased accuracy and precision of heparin and protamine dosing reduces blood loss and transfusion in patients undergoing primary cardiac operations.

Authors:  D R Jobes; G L Aitken; G W Shaffer
Journal:  J Thorac Cardiovasc Surg       Date:  1995-07       Impact factor: 5.209

View more
  2 in total

1.  Method to calculate the protamine dose necessary for reversal of heparin as a function of activated clotting time in patients undergoing cardiac surgery.

Authors:  Javier Suárez Cuenca; Pilar Gayoso Diz; Francisco Gude Sampedro; J Marcos Gómez Zincke; Helena Rey Acuña; M Manuela Fontanillo Fontanillo
Journal:  J Extra Corpor Technol       Date:  2013-12

2.  STS/SCA/AmSECT Clinical Practice Guidelines: Anticoagulation during Cardiopulmonary Bypass.

Authors:  Linda Shore-Lesserson; Robert A Baker; Victor Ferraris; Philip E Greilich; David Fitzgerald; Philip Roman; John Hammon
Journal:  J Extra Corpor Technol       Date:  2018-03
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.